	Application No.	Applicant(s)
Notice of Allowability	10/074,596	ROSENBLUM ET AL.
	Examiner	Art Unit
	Karen Cochrane Carlson, Ph.D.	1653
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. $\boxtimes$ This communication is responsive to <u>November 28, 2006</u> .		
2. The allowed claim(s) is/are <u>1-11,13-15,18,21-27,30-36,50-</u>	<u>57 and 59-61</u> .	
<ul> <li>3. Acknowledgment is made of a claim for foreign priority unally all bloomet claim for foreign priority unally all bloomet claim for foreign priority unall all bloomet claim for foreign priority unall all claim for foreign priority unall foreign priority unall claim for foreign priority documents have claim for foreign priority documents have documents ha</li></ul>	e been received. e been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	• •	complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		•
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.	
(a) ☐ including changes required by the Notice of Draftspers	son's Patent Drawing Review (PTO-	948) attached
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the C	Office action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 11/2005  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Dat 08), 7. ☑ Examiner's Amendo	e

Application/Control Number: 10/074,596

Art Unit: 1653

This Notice of Allowability is in response to the paper filed November 28, 2006 and to the agreement to the Examiner's Amendments presented below.

Claims 12, 19, 37-49, 58, and 62-98 have been canceled. Claims 1-11, 13-18, 20-36, 50-57, and 59-61 are currently pending.

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with David L. Parker on January 19, 2006.

## **Examiner's Amendments to the Claims:**

In Claim 7, please replace "claim 1" with — claim 6 —.

In Claim 8, please replace "claim 1" with --- claim 7 ---.

Please cancel Claim 16.

Please cancel Claim 17

- 20. (Currently Amended) A modified <u>gelonin</u> enzyme produced by the process comprising:
  - a) identifying one or more antigenic regions in the <u>gelonin</u> enzyme using an antibody;
  - b) removing one or more antigenic regions from the <u>gelonin</u> enzyme to form a modified <u>gelonin</u> enzyme; and
- e) determining that the modified <u>gelonin</u> enzyme has enzymatic activity; further wherein either i) the enzyme is gelonin toxin; or ii) a second polypeptide is conjugated or fused to the modified enzyme.

Please cancel Claims 28 and 29.

Application/Control Number: 10/074,596 Page 3

Art Unit: 1653

The following is an **Examiner's Statement of Reasons for Allowance**: The prior art of record does not teach or suggest gelonin comprising amino acids 110-210 of SEQ ID NO: 1 with at least 10 amino acids absent and at least 5 amino acids replaced, or modified gelonin comprising amino acids 110-210 of SEQ ID NO: 1 conjugated or fused to an antibody against a tumor antigen, or a functional modified gelonin having one or more antigenic regions removed.

Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Summary:** 

Claims 12, 16, 17, 19, 28, 29, 37-49, 58, and 62-98 have been canceled.

Claims 1-11, 13-15, 18, 21-27, 30-36, 50-57, and 59-61 are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER